Bonesupport Holding AB: 2 directors

Two Directors at Bonesupport Holding AB bought 248,711 shares at between 200.000SEK and 209.360SEK. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...

Arjo AB: 2 directors

Two Directors at Arjo AB bought 1,224,751 shares at between 29.999SEK and 30.177SEK. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

MedCap AB: 1 director

A director at MedCap AB maiden bought 350 shares at 630.000SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Solid quarter, solid conviction

Cautiously optimistic

Better organic growth and margins

Attractive growth case remains unchanged

Momentum is not improving

No change to growth case despite soft Q3

Back to organic decline on sales

Medtech back to growth

Fundamentals remain despite soft growth

Solid numbers should trigger a relief

Soft on sales but strong OCF

Impressive sales, but modest valuation upside

Higher sales drives beat in Q3

Fundamentals remain promising

Keep the growth coming

ACT to drive growth in Q3e

Improved sales momentum in Q3e